Trademark: 90845441
Word
TAVANTA
Status Date
Thursday, May 2, 2024
Filing Date
Friday, July 23, 2021
Published for Opposition
Tuesday, March 7, 2023
5 Housemark for a full line of prescription pharmaceuticals for the treatment of cancer, anal fissures, cystic fibrosis; pharmaceuticals for treatment of cancer, and cystic fibrosis; pharmaceuticals exhibiting efficient drug release for the treatment of cancer, cystic fibrosis, and anal fissures
42 Providing information about medical and scientific research; Providing information about medical and scientific research via a website
Jul 27, 2021
New Application Entered
Sep 23, 2021
New Application Office Supplied Data Entered
Apr 18, 2022
Assigned To Examiner
Apr 18, 2022
Non-Final Action Written
Apr 18, 2022
Non-Final Action E-Mailed
Apr 18, 2022
Notification Of Non-Final Action E-Mailed
Oct 18, 2022
Teas Response To Office Action Received
Oct 18, 2022
Correspondence Received In Law Office
Oct 19, 2022
Teas/Email Correspondence Entered
Oct 27, 2022
Suspension Letter Written
Oct 27, 2022
Letter Of Suspension E-Mailed
Oct 27, 2022
Notification Of Letter Of Suspension E-Mailed
Nov 29, 2022
Teas Response To Suspension Inquiry Received
Jan 30, 2023
Assigned To Lie
Jan 30, 2023
Correspondence Received In Law Office
Jan 30, 2023
Approved For Pub - Principal Register
Jan 30, 2023
Teas/Email Correspondence Entered
Feb 15, 2023
Notification Of Notice Of Publication E-Mailed
Mar 7, 2023
Published For Opposition
Mar 7, 2023
Official Gazette Publication Confirmation E-Mailed
May 2, 2023
Noa E-Mailed - Sou Required From Applicant
Nov 2, 2023
Sou Teas Extension Received
Nov 2, 2023
Sou Extension 1 Filed
Nov 2, 2023
Sou Extension 1 Granted
Nov 4, 2023
Notice Of Approval Of Extension Request E-Mailed
May 2, 2024
Sou Teas Extension Received
May 2, 2024
Sou Extension 2 Filed
May 2, 2024
Sou Extension 2 Granted
May 3, 2024
Notice Of Approval Of Extension Request E-Mailed
Trademark Alertz updated from USPTO on 2030-01-24
